
|Videos|September 21, 2016
Were PCSK9 Inhibitors Overhyped?
Author(s)Lauren Santye, Assistant Editor
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Advertisement
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
CagriSema Outperforms Semaglutide in Lowering HbA1C, Reducing Weight Across REIMAGINE Trials
2
Drug Shortages Are Declining, But Persistent Supply Chain Vulnerabilities Continue to Threaten Access
3
The Peptide Surge: Counseling Guidance on GLP-1s, Compounded Therapies, and What Patients Want to Know
4
FDA Adds a New Sunscreen to the OTC Repertoire
5



















































































































